Cure Today1d
Cabometyx Shows Promise for Treating Advanced NETs Originating in the GI Tract
A study showed Cabometyx improved time before disease progression in advanced digestive NETs compared with placebo.
Health on MSN1d
Restoring Gut Health: Strategies for a Healthier You
Your gut health—how well your gastrointestinal (GI) tract functions—can influence your overall health. Diet and lifestyle ...
The best time to take vitamin C for maximum health benefits
The human body can’t make vitamin C, so we have to get it through diet or supplements. If you're taking supplements, here's ...
Exelixis’s Cabozantinib Shows Promising Results for NET: Analyst Recommends ‘Buy’
Analyst David Lebowitz from Citi maintained a Buy rating on Exelixis (EXEL – Research Report) and keeping the price target at $38.00.Invest ...
Merck, Eisai post mixed Phase 3 data for Keytruda/ Lenvima in GIT cancer
Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...
How eating more fiber may help protect against dangerous bacteria like E. coli
The gut microbiome, which seems to be affected by our diet, plays an important role in reducing the growth of potentially ...
Exelixis reports on subgroup analysis of Phase 3 CABINET study
Exelixis (EXEL) announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...
Norovirus: What is it? Who's at risk? And why won't hand sanitizers work?
Norovirus—a highly contagious virus known for causing gastrointestinal distress—is making headlines this winter due to a ...
News Medical on MSN2d
Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patients
Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...